Pluri (PLUR) Revenue & Revenue Breakdown
Pluri Revenue Highlights
Latest Revenue (Y)
$326.00K
Latest Revenue (Q)
$96.00K
Pluri Revenue by Period
Pluri Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $326.00K | 13.59% |
| 2023-06-30 | $287.00K | 22.65% |
| 2022-06-30 | $234.00K | 100.00% |
| 2021-06-30 | - | -100.00% |
| 2020-06-30 | $23.00K | -57.41% |
| 2019-06-30 | $54.00K | 8.00% |
| 2018-06-30 | $50.00K | 100.00% |
| 2017-06-30 | - | -100.00% |
| 2016-06-30 | $2.85M | 651.19% |
| 2015-06-30 | $379.00K | - |
| 2014-06-30 | $379.00K | -44.18% |
| 2013-06-30 | $679.00K | -5.17% |
| 2012-06-30 | $716.00K | -142.57% |
| 2011-06-30 | $-1.68M | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2007-06-30 | - | 100.00% |
| 2006-06-30 | - | 100.00% |
| 2005-06-30 | - | 100.00% |
| 2004-06-30 | - | 100.00% |
| 2003-06-30 | - | 100.00% |
| 2002-06-30 | - | - |
Pluri generated $326.00K in revenue during NA 2024, up 13.59% compared to the previous quarter, and up 603.70% compared to the same period a year ago.
Pluri Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $96.00K | 35.21% |
| 2024-03-31 | $71.00K | -32.38% |
| 2023-12-31 | $105.00K | 94.44% |
| 2023-09-30 | $54.00K | -51.35% |
| 2023-06-30 | $111.00K | 27.59% |
| 2023-03-31 | $87.00K | 4250.00% |
| 2022-12-31 | $2.00K | -97.70% |
| 2022-09-30 | $87.00K | 100.00% |
| 2022-06-30 | - | -100.00% |
| 2022-03-31 | $234.00K | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | -100.00% |
| 2020-06-30 | $29.19M | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $23.00K | 100.00% |
| 2019-09-30 | - | -100.00% |
| 2019-06-30 | $20.60M | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $50.00K | 1150.00% |
| 2018-09-30 | $4.00K | -100.78% |
| 2018-06-30 | $-515.00K | 100.00% |
| 2018-03-31 | - | -100.00% |
| 2017-12-31 | $50.00K | -90.29% |
| 2017-09-30 | $515.00K | -98.27% |
| 2017-06-30 | $29.74M | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | -100.00% |
| 2015-12-31 | $2.75M | 2796.84% |
| 2015-09-30 | $95.00K | 1.06% |
| 2015-06-30 | $94.00K | -1.05% |
| 2015-03-31 | $95.00K | - |
| 2014-12-31 | $95.00K | - |
| 2014-09-30 | $95.00K | 1.06% |
| 2014-06-30 | $94.00K | -1.05% |
| 2014-03-31 | $95.00K | - |
| 2013-12-31 | $95.00K | - |
| 2013-09-30 | $95.00K | - |
| 2013-06-30 | $95.00K | -51.03% |
| 2013-03-31 | $194.00K | -0.51% |
| 2012-12-31 | $195.00K | - |
| 2012-09-30 | $195.00K | 93.07% |
| 2012-06-30 | $101.00K | -56.09% |
| 2012-03-31 | $230.00K | -0.43% |
| 2011-12-31 | $231.00K | 50.00% |
| 2011-09-30 | $154.00K | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2010-03-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2009-09-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2009-03-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2008-09-30 | - | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2008-03-31 | - | 100.00% |
| 2007-12-31 | - | - |
Pluri generated $96.00K in revenue during Q4 2024, up 35.21% compared to the previous quarter, and up 110.34% compared to the same period a year ago.
Pluri Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| STRO | Sutro Biopharma | $153.73M | $25.71M |
| RCUS | Arcus Biosciences | $117.00M | $48.00M |
| FATE | Fate Therapeutics | $63.53M | $6.77M |
| FHTX | Foghorn Therapeutics | $34.16M | $7.81M |
| CGEN | Compugen | $33.46M | $2.56M |
| SURF | Surface Oncology | $30.00M | - |
| MDWD | MediWound | $18.69M | $4.96M |
| EVGN | Evogene | $5.64M | $4.19M |
| BLRX | BioLineRx | $4.80M | $6.86M |
| DYAI | Dyadic | $2.90M | $1.96M |
| LUMO | Lumos Pharma | $2.05M | $488.00K |
| PLUR | Pluri | $326.00K | $96.00K |
| ENLV | Enlivex Therapeutics | - | - |
| ARDS | Aridis Pharmaceuticals | - | $417.00K |
| ELYM | Eliem Therapeutics | - | - |
| PPBT | Purple Biotech | - | - |
| CSBR | Champions Oncology | - | - |